Biomarkers of Cancer Risk and Their Use in Cancer Detection and Prevention

• US 20080187925A1
• Filed: 10/30/2007
• Published: 08/07/2008
• Est. Priority Date: 10/30/2006
• Status: Abandoned Application

• Current Assignee: Board of Regents of the University of Nebraska
• Original Assignee: Board of Regents of the University of Nebraska
• Inventors: Gaikwad, Nilesh W., Rogan, Eleanor G., Cavalieri, Ercole
• Application Number:
  US11/929,119
• Publication Number:
  US 20080187925A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A61K 47/55 the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• CPC Class Codes: A61K 47/554 the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
• CPC Class Codes: C12Q 1/68 involving nucleic acids

Abstract

Certain embodiments of the present invention provide methods for identifying subjects that have, or are at risk for developing, cancer and for determining the effectiveness of preventive cancer treatments.

Claims

1. A method for identifying a subject that has cancer, or is at an elevated risk for developing cancer, comprising determining the ratio of depurinating estrogen-DNA adducts to their respective metabolites and conjugates in a biological sample from the subject, wherein an increased level of the ratio, as compared to a control, indicates that the subject has cancer, or is at an elevated risk for developing cancer.

2. The method of claim 1, further comprising purifying the adducts, metabolites and conjugates from the sample using solid phase extraction (SPE).

3. The method of claim 2, further comprising analyzing the adducts, metabolites and conjugates utilizing ultraperformance liquid chromatography/tandem mass spectrometry (UPLC/MS-MS).

4. The method of claim 1, further comprising administering to those subjects who are at risk for developing cancer a therapy effective to reduce the risk of cancer.

5. The method of claim 4, wherein the therapy is effective to decrease the ratio of depurinating estrogen-DNA adducts to their respective metabolites and conjugates.

6. The method of claim 1, wherein the subject has, or is at an elevated risk for developing, breast cancer, prostate cancer, leukemia, non-Hodgkins lymphoma, colon cancer, pancreatic cancer, lung cancer, ovarian cancer, endometrial cancer, testicular cancer, kidney cancer or brain cancer.

7. The method of claim 1, wherein the sample is breast tissue, prostate tissue, urine, serum, sputum, nipple aspirate fluid, colon tissue, pancreas tissue, lung tissue, ovary tissue, endometrium, testis tissue, kidney tissue, or brain tissue.

8. The method of claim 1, wherein the subject is at an elevated risk for developing cancer.

9. The method of claim 1, wherein an adducts include an N3Ade adduct of 4-OHE₁(E₂) and an N7Gua adduct of 4-OHE₁(E₂).

10. The method of claim 1, wherein the subject is a male.

11. The method of claim 1, wherein the subject is a female.

12. A method for determining the effectiveness of a preventive cancer treatment, comprising determining the ratio of depurinating estrogen-DNA adducts to their respective metabolites and conjugates in a biological sample from the subject before and after a preventive cancer treatment, wherein a decrease in the level of the ratio after treatment indicates that the cancer treatment is effective to reduce the risk of cancer.

13. The method of claim 12, further comprising purifying the adducts, metabolites and conjugates from the sample using solid phase extraction (SPE).

14. The method of claim 13, further comprising analyzing the adducts, metabolites and conjugates utilizing ultraperformance liquid chromatography/tandem mass spectrometry (UPLC/MS-MS).

15. The method of claim 12, wherein the subject is at an elevated risk for developing cancer.

16. The method of claim 15, wherein the subject has, or is at an elevated risk for developing, breast cancer, prostate cancer, leukemia, non-Hodgkins lymphoma, colon cancer, pancreatic cancer, lung cancer, ovarian cancer, endometrial cancer, testicular cancer, kidney cancer or brain cancer.

17. The method of claim 12, wherein the sample is breast tissue, prostate tissue, urine, serum, sputum, nipple aspirate fluid, colon tissue, pancreas tissue, lung tissue, ovary tissue, endometrium, testis tissue, kidney tissue, or brain tissue.

18. The method of claim 12, wherein an adducts include an N3Ade adduct of 4-OHE₁(E₂) and an N7Gua adduct of 4-OHE₁(E₂).

19. The method of claim 12, wherein the subject is a male.

20. The method of claim 12, wherein the subject is a female.